Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241172 | 0.81 | DRD2 (0.41) | CYP1A2LMNAMEN1KMT2AABCB1 | |
| SCHEMBL26326254 | 0.80 | CYP1A2 (0.81) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL12040803 | 0.80 | CYP1A2 (0.65) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL15999373 | 0.80 | CYP1A2 (0.65) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL15999372 | 0.80 | CYP1A2 (0.65) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL21903451 | 0.78 | ALDH1A1 (0.47) | LMNAMEN1KMT2AADRB2 | |
| SCHEMBL15677167 | 0.76 | CYP1A2 (0.59) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL20356701 | 0.76 | CYP1A2 (0.59) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| Guaietolin SCHEMBL2108931 | 0.76 | CYP1A2 (0.74) | CYP1A2KDM4EAGTR1LMNAMEN1 | |
| SCHEMBL11016998 | 0.76 | CYSLTR2 (0.45) | CYP1A2AGTR1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023095615-A1 | EPOXY RESIN COMPOSITION, CURED PRODUCT THEREOF, AND LAMINATE | DIC株式会社 | 2023-06-01 | — | — | WO | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | CYP1A2 3242/4885KDM4E 4445/4885AGTR1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.